Cargando…

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmeno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soe, Lin H, Wurz, Gregory T, Kao, Chiao-Jung, DeGregorio, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792833/ https://www.ncbi.nlm.nih.gov/pubmed/24109197 http://dx.doi.org/10.2147/IJWH.S39146

Ejemplares similares

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015)

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
por: del Carmen Pingarrón Santofimia, María, et al.
Publicado: (2020)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial
por: Constantine, G., et al.
Publicado: (2015)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window
por: DeGregorio, Michael W., et al.
Publicado: (2021)

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy
por: Kingsberg, SA, et al.
Publicado: (2010)

Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy
por: Kao, Chiao-Jung, et al.
Publicado: (2013)

Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study
por: Goldstein, Sue W., et al.
Publicado: (2018)

29-year-old with dyspareunia and vulvar mass: An unusual diagnosis of Bartholin's gland carcinoma
por: Billingsley, Caroline, et al.
Publicado: (2018)

Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
por: Pięta, Wojciech, et al.
Publicado: (2021)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
por: DeGregorio, Michael, et al.
Publicado: (2012)

Indeterminacy of cannabis impairment and ∆(9)-tetrahydrocannabinol (∆(9)-THC) levels in blood and breath
por: Wurz, Gregory T., et al.
Publicado: (2022)

Notes on Dyspareunia
Publicado: (1909)

Risk of non-resumption of vaginal sex and dyspareunia among cesarean-delivered women
por: Doke, Prakash Prabhakarrao, et al.
Publicado: (2021)

Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ(8)-tetrahydrocannabinol: case studies
por: Wurz, Gregory T., et al.
Publicado: (2022)

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
por: Nappi, R. E., et al.
Publicado: (2016)

Hypnotism in the Treatment of Dyspareunia
por: Bryan, Douglas
Publicado: (1909)

Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model
por: Wurz, Gregory T, et al.
Publicado: (2013)

Hypoxia as a potential cause of dyspareunia
por: Hurt, Karel, et al.
Publicado: (2023)

Endometriosis and dyspareunia: Solving the enigma
por: Jimenez, Jose Carlos Vilches, et al.
Publicado: (2023)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
por: Nordstrom, Beth L., et al.
Publicado: (2022)

Deep Dyspareunia, Superficial Dyspareunia, and Infertility Concerns Among Women With Endometriosis: A Cross-Sectional Study
por: Wahl, Kate J., et al.
Publicado: (2020)

Dyspareunia associated with a pelvic digit
por: Evangelista, P, et al.
Publicado: (2011)

Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis
por: Simon, James A., et al.
Publicado: (2023)

Human papillomavirus in vulvar and vaginal carcinoma cell lines
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_4f0ib7a44hed1j4ihek7ltoa9b